Biotech startups that raised Series B in North America
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Prolific Machines | Emeryville | Series B | $50.0M | 2026-10-14 |
| Multiply Labs | San Francisco | Series B | $75.0M | 2026-10-06 |
| Tiny Health | Austin | Series B | $33.0M | 2026-09-29 |
| Evvy | New York | Series B | $40.0M | 2026-09-15 |
| Moonwalk Biosciences | South San Francisco | Series B | $70.0M | 2026-09-08 |
| Superluminal Medicines | Boston | Series B | $65.5M | 2026-09-03 |
| N-Power Medicine | Redwood City | Series B | $32.0M | 2026-09-01 |
| Simnova | Cambridge | Series B | $59.3M | 2026-08-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 701 biotech startups in North America whose last round is Series B have raised $52.2B in total.
- 84 of them closed their most recent round in the last 12 months, $5.5B combined.
- The largest of those rounds is Ollin Biosciences' $330.0M Series B, dated June 2026.
- The most recent is Rgenta Therapeutics' $41.9M Series B on 3 November 2026.
- RA Capital Management is an investor in 12 of them, more than any other fund.
- Health care is the most common other sector, with 626 companies (89%).
- 15% were founded in 2020 or later; the median founding year is 2014.
- The most common team size is 11 to 50 employees (52% of companies with a recorded size).
- 4 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 701| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Prolific Machines | Prolific Machines develops light-controlled gene expression systems for producing therapeutics. | Artificial intelligence | Emeryville, United States | Series B | $50.0M | 2026-10-14 | $147.0M | SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 | 51 to 100 | 2020 |
| Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | San Francisco, United States | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
| Tiny Health | Tiny Health offers at-home microbiome testing and health insights for babies, children, adults, and pregnant people. | Biotech | Austin, United States | Series B | $33.0M | 2026-09-29 | $46.0M | TheVentureCity, Next Coast Ventures, Spero Ventures +2 | 11 to 50 | 2020 |
| Evvy | Evvy offers an AI-driven precision medicine platform focused on women's health. | Artificial intelligence | New York, United States | Series B | $40.0M | 2026-09-15 | $59.0M | General Catalyst, BoxGroup, Left Lane Capital +2 | 11 to 50 | 2021 |
| Moonwalk Biosciences | Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. | Artificial intelligence | South San Francisco, United States | Series B | $70.0M | 2026-09-08 | $127.0M | Google Ventures, Khosla Ventures, ARCH Venture Partners +2 | 11 to 50 | 2022 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston, United States | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| N-Power Medicine | N-Power Medicine is a biotechnology company that uses AI to offer clinical research and drug development services. | Artificial intelligence | Redwood City, United States | Series B | $32.0M | 2026-09-01 | $104.0M | Merck Global Health Innovation Fund | 101 to 250 | 2021 |
| Simnova | Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. | Biotech | Cambridge, United States | Series B | $59.3M | 2026-08-18 | $87.2M | Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 | 51 to 100 | 2019 |
| InduPro | InduPro develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease. | Biotech | Seattle, United States | Series B | $77.0M | 2026-08-12 | $162.0M | Euclidean Capital, The Column Group, Vida Ventures +1 | 51 to 100 | 2022 |
| Aureka Biotechnologies | Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. | Artificial intelligence | Laguna Hills, United States | Series B | $100.0M | 2026-08-10 | $168.4M | K2VC, NRL Capital | 11 to 50 | 2023 |
| Theradaptive | Theradaptive develops protein therapeutics for spine, orthopedics, and targeted immuno-oncology. | Biotech | Frederick, United States | Series B | $36.2M | 2026-08-04 | $71.0M | Maryland Stem Cell Research Fund (MSCRF) | 11 to 50 | 2016 |
| Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City, United States | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| Kuehnle Agrosystems | Kuehnle Agrosystems develops plant-based systems to produce biologically active compounds through biotech research. | Biotech | Honolulu, United States | Series B | $3.0M | 2026-07-06 | $11.8M | S2G Investments, Cavallo Ventures, Aqua Spark +2 | 1 to 10 | 2007 |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development develops nanoparticle technology to reset immune systems in multiple sclerosis patients. | Biotech | Skokie, United States | Series B | $50.0M | 2026-06-18 | $185.5M | Alpha Wave Global, Bristol-Myers Squibb, Alpha Wave Ventures +2 | 51 to 100 | 2015 |
| Elemental Machines | Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. | Artificial intelligence | Cambridge, United States | Series B | $5.7M | 2026-05-27 | $66.5M | Founders Fund, Tau Ventures, Rock Health Capital +2 | 11 to 50 | 2015 |
| LTZ Therapeutics | LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. | Biotech | San Francisco, United States | Series B | $38.0M | 2026-05-06 | $125.0M | Qiming Venture Partners, Shunwei Capital, K2VC +1 | 11 to 50 | 2022 |
| Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Cambridge, United States | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
| Ambrosia Biosciences | Ambrosia Biosciences provides drug development services for small molecule therapies targeting obesity and metabolic disorders. | Biotech | Boulder, United States | Series B | $100.0M | 2026-03-31 | $141.0M | Boulder Ventures, Biotechnology Value Fund | 11 to 50 | 2024 |
| Unnatural Products | Unnatural Products is a biotech company that develops macrocyclic peptide drug therapies. | Artificial intelligence | Santa Cruz, United States | Series B | $45.0M | 2026-03-16 | $83.0M | Abstract, Better Ventures, Artis Ventures +2 | 11 to 50 | 2017 |
| Atavistik Bio | Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. | Biotech | Cambridge, United States | Series B | $40.0M | 2026-03-05 | $260.0M | Lux Capital, The Column Group, Nextech Invest | 11 to 50 | 2021 |
| BreezeBio | BreezeBio is a biotechnology company that develops genetic therapies using non-viral delivery to clinically important tissues. | Artificial intelligence | Brisbane, United States | Series B | $60.0M | 2026-02-25 | $127.7M | Sequoia Capital, National Science Foundation, Qiming Venture Partners +1 | 51 to 100 | 2016 |
| Kainova Therapeutics | Kainova Therapeutics develops therapies that modulate GPCRs to treat immuno-oncology and inflammatory conditions. | Biotech | Montréal, Canada | Series B | $23.5M | 2026-02-09 | $123.6M | Bpifrance, Sofinnova Partners, Andera Partners +1 | 11 to 50 | 2001 |
| Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego, United States | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Boston, United States | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown, United States | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| Nocion Therapeutics | Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. | Biotech | Cambridge, United States | Series B | $23.0M | 2026-01-07 | $134.0M | Canaan Partners, F-Prime, OUP (Osage University Partners) +2 | 11 to 50 | 2017 |
| Myrtelle | Myrtelle is a gene therapy company that runs clinical trials for rare monogenetic disorders. | Biotech | Wakefield, United States | Series B | $30.5M | 2025-12-23 | $57.6M | Panacea Venture | 11 to 50 | 2020 |
| Manifold | Manifold provides machine learning tools that analyze operational data to support industrial and energy decisions. | Artificial intelligence | Newton, United States | Series B | $18.0M | 2025-12-18 | $40.5M | TQ Ventures, Calibrate Ventures, SK Ventures +1 | 101 to 250 | 2016 |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals develops and commercializes therapeutics for rare and age-related diseases. | Biotech | San Francisco, United States | Series B | $55.0M | 2025-12-16 | $142.0M | Sofinnova Investments, venBio Partners, Apollo Health Ventures | 1 to 10 | 2012 |
| Alphyn Biologics | Alphyn Biologics develops Multi-Target Therapeutics for treating skin diseases. | Biotech | Cincinnati, United States | Series B | $25.0M | 2025-12-12 | $36.8M | Angel Physicians Fund, Serial Stage Venture Partners | 1 to 10 | 2019 |
Table 1. Biotech startups that raised Series B in North America: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 701.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego, United States | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 2 | Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown, United States | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| 3 | Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City, United States | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| 4 | Sanegene Bio | Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. | Biotech | Woburn, United States | Series B | $110.0M | 2025-12-08 | $240.0M | Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 | 51 to 100 | 2021 |
| 5 | Profluent Bio | Profluent Bio designs new proteins and gene-editing tools using AI for medicine, agriculture, and science. | Artificial intelligence | Emeryville, United States | Series B | $106.0M | 2025-11-19 | $150.0M | Insight Partners, Spark Capital, AIX Ventures +1 | 11 to 50 | 2022 |
| 6 | Aureka Biotechnologies | Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. | Artificial intelligence | Laguna Hills, United States | Series B | $100.0M | 2026-08-10 | $168.4M | K2VC, NRL Capital | 11 to 50 | 2023 |
| 7 | Ambrosia Biosciences | Ambrosia Biosciences provides drug development services for small molecule therapies targeting obesity and metabolic disorders. | Biotech | Boulder, United States | Series B | $100.0M | 2026-03-31 | $141.0M | Boulder Ventures, Biotechnology Value Fund | 11 to 50 | 2024 |
| 8 | BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | San Diego, United States | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| 9 | InduPro | InduPro develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease. | Biotech | Seattle, United States | Series B | $77.0M | 2026-08-12 | $162.0M | Euclidean Capital, The Column Group, Vida Ventures +1 | 51 to 100 | 2022 |
| 10 | Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | San Francisco, United States | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
Table 2. Biotech startups that raised Series B in North America: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Management | Startup incubator | Boston, United States | 12 | 2% | 3 | Superluminal Medicines, Claris Biotherapeutics, Diagonal Therapeutics |
| 2 | OrbiMed | Private equity firm | New York, United States | 11 | 2% | 2 | Mirador Therapeutics, BlossomHill Therapeutics |
| 3 | Google Ventures | Corporate venture arm | San Francisco, United States | 8 | 1% | 1 | Moonwalk Biosciences |
| 4 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 8 | 1% | 2 | Moonwalk Biosciences, Mirador Therapeutics |
| 5 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 8 | 1% | 1 | Kytopen |
| 6 | Alumni Ventures | Angel group | Manchester, United States | 8 | 1% | 1 | Sorcero |
| 7 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 7 | 1% | 2 | Cour Pharmaceuticals Development, Precede Biosciences |
| 8 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 7 | 1% | ||
| 9 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 6 | 1% | 2 | Kytopen, BreezeBio |
| 10 | Digitalis Ventures | Venture capital firm | New York, United States | 5 | 1% | 1 | Elemental Machines |
| 11 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 5 | 1% | ||
| 12 | Samsara BioCapital | Private equity firm | Palo Alto, United States | 5 | 1% | ||
| 13 | Alpha Wave Global | Private equity firm | Miami, United States | 4 | 1% | 2 | Moonwalk Biosciences, Cour Pharmaceuticals Development |
| 14 | Insight Partners | Private equity firm | New York, United States | 4 | 1% | 2 | Superluminal Medicines, Profluent Bio |
| 15 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 4 | 1% | 3 | LTZ Therapeutics, BreezeBio, Sanegene Bio |
Table 3. Biotech startups that raised Series B in North America: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 626 | 89% | $48.3B |
| Software | 86 | 12% | $6.0B |
| Artificial intelligence | 46 | 7% | $4.2B |
| Hardware | 25 | 4% | $741.4M |
| Cybersecurity | 7 | 1% | $407.4M |
| Fintech | 6 | 1% | $359.3M |
| Energy | 5 | 1% | $142.5M |
| Commerce | 4 | 1% | $149.4M |
Table 4. Biotech startups that raised Series B in North America by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 701 | 100% | $26.0M |
Table 5. Biotech startups that raised Series B in North America by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 682 | 97% |
| Canada | 19 | 3% |
Table 6. Biotech startups that raised Series B in North America by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Biotech startups that raised Series B in North America by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 2 | 2% | $63.3M |
| October 2026 | 6 | 7% | $545.0M |
| September 2026 | 9 | 11% | $284.0M |
| August 2026 | 8 | 10% | $556.2M |
| July 2026 | 5 | 6% | $253.4M |
| June 2026 | 9 | 11% | $1.0B |
| May 2026 | 4 | 5% | $192.2M |
| April 2026 | 5 | 6% | $270.6M |
| March 2026 | 5 | 6% | $351.0M |
| February 2026 | 5 | 6% | $245.0M |
| January 2026 | 11 | 13% | $801.5M |
| December 2025 | 12 | 14% | $700.5M |
| November 2025 | 3 | 4% | $207.7M |
Table 8. Biotech startups that raised Series B in North America: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 69 | 10% | $4.6B |
| 2025 | 68 | 10% | $4.3B |
| 2024 | 59 | 8% | $3.8B |
| 2023 | 54 | 8% | $3.1B |
| 2022 | 52 | 7% | $2.3B |
| 2021 | 72 | 10% | $4.4B |
Table 9. Biotech startups that raised Series B in North America by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 16 | 2% |
| 2020 to 2022 | 90 | 13% |
| 2015 to 2019 | 229 | 33% |
| 2010 to 2014 | 140 | 20% |
| Before 2010 | 225 | 32% |
Table 10. Biotech startups that raised Series B in North America by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 142 | 21% |
| 11 to 50 | 361 | 52% |
| 51 to 100 | 120 | 17% |
| 101 to 250 | 42 | 6% |
| 251 to 500 | 7 | 1% |
| 501 to 1,000 | 7 | 1% |
| 1,001 to 5,000 | 3 | 0% |
| 5,001 to 10,000 | 2 | 0% |
| 10,001 or more | 6 | 1% |
Table 11. Biotech startups that raised Series B in North America by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in North America. On 16 November 2026 that is 701 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 701 rows: 47 have no round amount, 0 no city and 88 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in North America whose last round is Series B are on the list?
- 701, in the file dated 16 November 2026. 84 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 701 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.